Korro Bio, Inc. develops genetic medicines based on RNA editing for rare and highly prevalent diseases. The company uses its OPERA® oligonucleotide promoted editing of RNA platform to design therapies that harness endogenous RNA editing for precise, transient single-base edits.
Korro Bio news commonly covers corporate updates, financial results, scientific presentations, investor conference activity, and pipeline progress. Recurring program topics include KRRO-121 for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research for alpha-1 antitrypsin deficiency, private placement financings, equity-inducement grants, and other capital-structure and governance updates.
Korro Bio (KRRO) reported preclinical results for KRRO-111, its RNA-editing candidate for alpha-1 antitrypsin deficiency affecting the lungs and liver.
In repeat-dose NSG-PiZ mouse studies, editing of SERPINA1 messenger RNA reached 96%; functional M-AAT comprised 93% of circulating AAT. Total AAT reached 172 μM, approximately six-fold versus vehicle, at Day 57. In a separate immunocompetent C57BL/6-PiZ mouse study, whole-liver levels of pathogenic Z-AAT fell 95% versus vehicle at Day 57. Single-dose studies produced up to 91% editing, with M-AAT accounting for up to 88% of circulating AAT; both responses remained detectable through at least Day 42.
Korro expects a regulatory submission in the first half of 2027 and aims to advance KRRO-111 into the clinic in that period. These findings concern preclinical studies, not patient outcomes.
Korro Bio (KRRO) granted stock options covering 4,000 shares to two newly hired employees, effective October 14, 2026. The exercise price is $8.88 per share, matching the Nasdaq closing price on the effective date. The options have a ten-year term and vest over four years: 25% on each employee’s first start-date anniversary, followed by 36 equal monthly installments for the remaining 75%, subject to continued service.
The independent Compensation Committee approved the grants under the 2026 Inducement Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Korro Bio (Nasdaq: KRRO) has dosed the first cohort of healthy volunteers in ANCHOR, its Phase 1/2 clinical trial of KRRO-121.
The cohort received a single 2mg/kg dose. KRRO-121 is being developed to treat hyperammonemia, an accumulation of ammonia in the blood, in patients with urea cycle disorders (UCDs) and hepatic encephalopathy. ANCHOR is currently enrolling healthy volunteers in Australia. Its placebo-controlled Phase 1 studies will assess safety, tolerability and pharmacokinetics, how the drug moves through the body, in up to 50 participants using single and multiple ascending doses.
Phase 2 will evaluate multiple doses in up to 15 UCD patients across all UCD genotypes, assessing safety, tolerability, pharmacokinetics and clinical activity, subject to regulatory approval. Korro expects UCD patient dosing to begin in the first half of 2027, with an interim clinical readout in the second half of 2027.
Korro Bio (KRRO) granted nonstatutory stock options under its 2026 Inducement Plan to three newly hired employees, effective September 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options cover an aggregate of 5,000 shares of common stock at an exercise price of $12.93 per share, equal to the closing price on the grant date. Each option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of the employee’s start date and the remaining 75% vesting in 36 equal monthly installments, subject to continued service. The grants were approved by Korro’s independent Compensation Committee as an inducement for employment.
Korro (Nasdaq: KRRO) announced that President & CEO Ram Aiyar will participate in two investor conferences: the Citi 2026 Biopharma Back to School Summit on September 9, 2026 at 8:40 AM ET, and the 2026 Cantor Global Healthcare Conference on September 10, 2026 at 1:00 PM ET. Both appearances will be fireside chats moderated by biotech equity research analysts. Korro is a Cambridge, Massachusetts-based biopharmaceutical company developing RNA-editing genetic medicines using its OPERA platform and plans to use its Investor Relations website and social channels for Regulation FD-compliant disclosures.
Korro Bio (Nasdaq: KRRO) reported that its Compensation Committee granted a non-statutory stock option to one newly hired employee under the company’s 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The option covers 600 shares of common stock at an exercise price of $13.35 per share, equal to the August 12, 2026 Nasdaq closing price. It has a 10-year term and vests over four years: 25% on the first employment anniversary and 75% in 36 equal monthly installments thereafter, subject to continued service. Korro develops genetic medicines using its OPERA RNA-editing platform.
Korro (Nasdaq: KRRO) reported second quarter 2026 results and advanced its RNA-editing pipeline. Cash, cash equivalents and marketable securities were $137.9 million at June 30, 2026, up from $85.2 million at year-end 2025, with a stated cash runway into the second half of 2028.
The company reported no collaboration revenue versus $1.5 million a year earlier, reflecting a 12‑month pause of its Novo Nordisk collaboration. R&D expenses fell to $13.6 million from $20.1 million, G&A to $6.5 million from $7.3 million, and net loss narrowed to $18.9 million from $25.8 million.
Korro received EMA Orphan Drug Designation for KRRO-121 for urea cycle disorders, remained on track to start first-in-human trials in the second half of 2026, and nominated KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency with >90% RNA-editing and substantial protein correction in preclinical models.
Korro Bio (Nasdaq: KRRO) granted non-statutory stock options to seven newly hired employees under its 2026 Inducement Plan, compliant with Nasdaq Listing Rule 5635(c)(4). Four employees received options for a total of 6,000 shares at an exercise price of $10.59 per share, effective June 10, 2026, and three employees received options for a total of 17,000 shares at $14.72 per share, effective July 8, 2026.
The options have ten-year terms and vest over four years, with 25% vesting on the first employment anniversary and the remaining 75% vesting in 36 equal monthly installments, subject to continued service. According to Korro Bio, the independent Compensation Committee approved these inducement awards as a material condition of employment.
Korro (Nasdaq: KRRO) announced that CEO and President Ram Aiyar, Ph.D., will present at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026, at 4:20 pm ET, highlighting Korro’s OPERA RNA-editing platform and genetic medicine focus.
Korro Bio (Nasdaq: KRRO) selected KRRO-111 as a development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), a genetic liver and lung disorder. KRRO-111 is a subcutaneous GalNAc-conjugated oligonucleotide designed to repair the pathogenic SERPINA1 SNV via RNA editing.
In preclinical PiZZ mouse studies, KRRO-111 achieved >90% editing of AAT transcripts, ~90% functional M-AAT protein in plasma, ~95% reduction in non-inclusion Z-AAT at days 28 and 56, and ~69% reduction of inclusion-associated Z-AAT at day 28, suggesting potential improvement in both liver and lung manifestations.